DE69127615D1 - Transformierte Erythrozyten, Verfahren zu deren Herstellung, und ihre Verwendung in pharmazeutischen Zusammensetzungen - Google Patents

Transformierte Erythrozyten, Verfahren zu deren Herstellung, und ihre Verwendung in pharmazeutischen Zusammensetzungen

Info

Publication number
DE69127615D1
DE69127615D1 DE69127615T DE69127615T DE69127615D1 DE 69127615 D1 DE69127615 D1 DE 69127615D1 DE 69127615 T DE69127615 T DE 69127615T DE 69127615 T DE69127615 T DE 69127615T DE 69127615 D1 DE69127615 D1 DE 69127615D1
Authority
DE
Germany
Prior art keywords
processes
preparation
pharmaceutical compositions
erythrocytes
transformed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69127615T
Other languages
English (en)
Other versions
DE69127615T2 (de
Inventor
Mauro Magnani
Luigia Rossi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EUROP COMMUNITIES
Original Assignee
EUROP COMMUNITIES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EUROP COMMUNITIES filed Critical EUROP COMMUNITIES
Publication of DE69127615D1 publication Critical patent/DE69127615D1/de
Application granted granted Critical
Publication of DE69127615T2 publication Critical patent/DE69127615T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5063Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068Cell membranes or bacterial membranes enclosing drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/18Erythrocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69127615T 1991-06-14 1991-06-14 Transformierte Erythrozyten, Verfahren zu deren Herstellung, und ihre Verwendung in pharmazeutischen Zusammensetzungen Expired - Fee Related DE69127615T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91401602A EP0517986B1 (de) 1991-06-14 1991-06-14 Transformierte Erythrozyten, Verfahren zu deren Herstellung, und ihre Verwendung in pharmazeutischen Zusammensetzungen

Publications (2)

Publication Number Publication Date
DE69127615D1 true DE69127615D1 (de) 1997-10-16
DE69127615T2 DE69127615T2 (de) 1998-03-19

Family

ID=8208584

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69127615T Expired - Fee Related DE69127615T2 (de) 1991-06-14 1991-06-14 Transformierte Erythrozyten, Verfahren zu deren Herstellung, und ihre Verwendung in pharmazeutischen Zusammensetzungen

Country Status (10)

Country Link
US (1) US5753221A (de)
EP (1) EP0517986B1 (de)
JP (1) JPH06510742A (de)
AT (1) ATE157879T1 (de)
CA (1) CA2102619A1 (de)
DE (1) DE69127615T2 (de)
DK (1) DK0517986T3 (de)
ES (1) ES2109260T3 (de)
GR (1) GR3025488T3 (de)
WO (1) WO1992022306A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409710A (en) * 1993-04-20 1995-04-25 Endocon, Inc. Foam cell drug delivery
ES2129893T3 (es) * 1994-07-15 1999-06-16 Biosearch Italia Spa Dinucleosido-5',5'-pirofosfatos.
DE69732225T2 (de) * 1997-05-05 2005-06-23 Dideco S.R.L., Mirandola Verfahren zur Verkapselung von biologisch aktiven Stoffen in Erythrocyten und Gerät dafür
ATE316757T1 (de) 1998-05-26 2006-02-15 Lifecell Corp Cryokonservierung menschlicher roter blutzellen
US20100042072A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US8211656B2 (en) 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
US20110070153A1 (en) * 2008-08-13 2011-03-24 Searete, Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
US20100040546A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20110213193A1 (en) * 2008-08-28 2011-09-01 The Florida International University Board Of Trustees Magnetic Nanodelivery of Therapeutic Agents Across the Blood Brain Barrier
CA2930665A1 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
CA2944492A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
US20190290686A1 (en) 2017-12-23 2019-09-26 Rubius Therapeutics, Inc. Artificial antigen presenting cells and methods of use
AU2019232012A1 (en) 2018-03-08 2020-09-24 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating cancer and infectious diseases
CN114007627A (zh) 2019-04-26 2022-02-01 鲁比厄斯治疗法股份有限公司 包含去核类红细胞的缓冲组合物
CN114127252A (zh) 2019-05-24 2022-03-01 鲁比厄斯治疗法股份有限公司 生成去核红系细胞的方法
WO2021092052A1 (en) 2019-11-04 2021-05-14 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells using myo-inositol
KR20220093196A (ko) 2019-11-04 2022-07-05 루비우스 테라퓨틱스, 아이엔씨. 타우린 또는 하이포타우린을 사용하여 제핵 적혈구 세포를 생성하는 방법
TW202241470A (zh) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 治療人類個體腫瘤之方法
TW202241471A (zh) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 提高個體中NKp30陽性淋巴球的方法及其用途
WO2022197548A1 (en) 2021-03-14 2022-09-22 Rubius Therapeutics, Inc. Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof
TW202317179A (zh) 2021-06-03 2023-05-01 美商盧比亞斯治療公司 在個體中治療hpv16-陽性或hpv16-相關的癌症之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2529463B1 (fr) * 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
IL86650A0 (en) * 1987-06-30 1988-11-30 Biophor Corp Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
FR2653561A1 (fr) * 1989-10-19 1991-04-26 Fondation Nale Transfusion San Hetero-anticorps anti-rhd et composition pharmaceutique les contenant.

Also Published As

Publication number Publication date
WO1992022306A1 (en) 1992-12-23
ES2109260T3 (es) 1998-01-16
ATE157879T1 (de) 1997-09-15
GR3025488T3 (en) 1998-02-27
CA2102619A1 (en) 1992-12-15
EP0517986A1 (de) 1992-12-16
EP0517986B1 (de) 1997-09-10
US5753221A (en) 1998-05-19
DK0517986T3 (da) 1998-03-30
DE69127615T2 (de) 1998-03-19
JPH06510742A (ja) 1994-12-01

Similar Documents

Publication Publication Date Title
DE69127615D1 (de) Transformierte Erythrozyten, Verfahren zu deren Herstellung, und ihre Verwendung in pharmazeutischen Zusammensetzungen
ATE56021T1 (de) Desulfatohirudine, verfahren zu ihrer herstellung und pharmazeutische mittel.
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
NO902800D0 (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
DE59209965D1 (de) Chinoxaline, Verfahren zu ihrer Herstellung und ihre Verwendung
DE68906609D1 (de) Dopamin-vorlaeufer.
NL960024I1 (nl) Farmaceutisch preparaat omvattend 3'-deoxythymidine-2'-een (3'-deoxy-2',3'-didehydrothymidine) voor de behandeling van met retrovirus gesmette patiënten.
FI945975A (fi) Haarautuneella aminoryhmällä substituoituja tiatsoleja, menetelmiä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
DE59200277D1 (de) Substituierte Diaminophthalimide und Analoga.
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
ATE127020T1 (de) Pharmazeutische zusammensetzungen mit eierschalenbestandteilen und ihre herstellung und verwendung.
ATE80039T1 (de) Pharmazeutische zusammensetzung, enthaltend 2',3'-dideoxycytidin-2'-en(2',3'-dideoxy-2',3'didehydrocytidin) zur behandlung von mit retrovirus infizierten patienten.
DE3887068D1 (de) 2,2-Dimethylchromenderivate, Verfahren zur Herstellung und diese enthaltende pharmazeutische Zusammenstellungen.
ATE66230T1 (de) Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
FR2707638B1 (fr) Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique.
ATE141796T1 (de) 2',5'-oligoadenylat-derivate zur verwendung als heilmittel
DE59008921D1 (de) Dibenzo(1,5)dioxocin-5-one-Derivate, ihre Verwendung in Arzneimitteln und Verfahren zu ihrer Herstellung.
FR2635527B1 (fr) Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
DE69402004D1 (de) Beta-mercapto-propanamidderivate verwendbar zur Behandlung kardiovaskularer Krankheiten oder Erkrankungen
EP0129891A3 (de) Chinazolinon-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
ATE112276T1 (de) Aryl-chinolyl-substituierte 1,4-dihydropyridin- dicarbonsäurederivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.
ATE37370T1 (de) Triazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
ATE123497T1 (de) Substituierte pyridin-verbindungen, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
KR890001555A (ko) 요산 배설용 조성물
ATE101119T1 (de) Butensaeure-amide, deren salze, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee